MA13.08 A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation
نویسندگان
چکیده
Prior work presented by us identified, in both pre-clinical models and a phase 2 clinical trial of sapanisertib (NCT02417701), that lung squamous cell carcinomas (LUSC) harboring NRF2 activating mutations are sensitive to treatment with the TORC1/2 inhibitor sapanisertib. Further preclinical data suggests suppression glycolysis is potentiated targeting glutaminolysis helps fuel Krebs cycle, which actionable via co-treatment activated NSCLC glutaminase telaglenastat (CB-839), leading synergistic anti-tumor activity.
منابع مشابه
Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
Background Mucin 1 (MUC1), a glycoprotein normally expressed at low levels on the apical borders of secretory epithelial cells, is overexpressed and aberrantly glycosylated in many cancers. ONT 10 is a therapeutic peptide vaccine incorporating a synthetic glycolipopeptide MUC1 antigen, M40Tn6, and novel synthetic TLR-4 agonist, PET Lipid A, in a liposomal formulation designed to elicit antibody...
متن کاملSafety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer
BACKGROUND Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on Intravenous application are limited. METHODS An aqueous extract from pine-mistletoe was used to investigate maximum tolerable dose (MTD) and safety of intravenous application. It was infused once weekly for 3 weeks in patients with advanced cancer. Any type of cancer was ...
متن کاملPhase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
Veliparib (ABT-888) is a potent, orally bioavailable poly(ADP-ribose) polymerase-1 and -2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single-agent veliparib in Japanese patients with advanced solid tumors. Eligible patients were assigned to treatment with veliparib at 200 or 400 mg dose; veliparib was self-admi...
متن کاملTreatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.
PURPOSE Humanized antibody hPAM4 specifically binds a mucin glycoprotein expressed in pancreatic adenocarcinomas. This phase I study evaluated a single dose of (90)Y-clivatuzumab tetraxetan ((90)Y-labeled hPAM4) in patients with advanced pancreatic cancer. EXPERIMENTAL DESIGN Twenty-one patients (4 stage III; 17 stage IV) received (111)In-hPAM4 for imaging and serum sampling before (90)Y-hPAM...
متن کاملA phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
PURPOSE The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors. This phase I study sought an appropriate LY2275796 dose in patients with advanced tumors. EXPERIMENTAL DESIGN A 3-day loading dose, then weekly maintenance doses, were given to 1 to 3 patient cohorts, beginning ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2022
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2022.07.153